CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Caris Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$30.71+0.15 (+0.49%)
Close on Oct 19, 2026
- Market cap
- $8.69B
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
17 of Caris Life Sciences's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Sep 14, 2026 | Sep 14, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 5, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 5, 2026 | Aug 5, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 4, 2026 | Jun 5, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 8, 2026 | SEC EDGAR |
| Current report | 8-K | May 7, 2026 | May 7, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | Jun 4, 2026 | Apr 23, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 1, 2026 | Apr 2, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 3, 2026 | SEC EDGAR |
| Current report | 8-K | Feb 26, 2026 | Feb 26, 2026 | SEC EDGAR |
| Current report | 8-K | Jan 12, 2026 | Jan 12, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2025 | Nov 5, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 5, 2025 | Nov 5, 2025 | SEC EDGAR |
| Current report | 8-K | Oct 30, 2025 | Oct 30, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2025 | Aug 12, 2025 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2025 | Aug 12, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 20, 2025 | Jun 20, 2025 | SEC EDGAR |